All lobbying filings

DLA PIPER LLP (US)

DLA PIPER LLP (US) filed a Q3 report for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA on October 20, 2026, reporting $60,000 in lobbying income.

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Trade association of innovative biopharmaceutical research companies.

All filings by DLA PIPER LLP (US) · Everything PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 7

Health Issues

S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.

Medicare/Medicaid

Medicare policies.

Budget/Appropriations

Healthcare provisions in appropriations and budget legislation.

Defense

National security issues related to pharmaceutical industry, including supply chain.

Trade (domestic/foreign)

Trade policies and agreements, including IP protections, and administrative tariff actions.

Pharmacy

Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.

Intellectual property protections and enforcement. Biopharmaceutical patent policy.

Bills named in this filing 1

S. 832
EPIC Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.